-Pain intensity through 24 hours reduced by 69%-Pain intensity through 72 hours reduced by 40%-Time to first use of opiate rescue medication increased by 488%-32% of patients received no opiate […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2015-09-22 16:05:162015-09-23 19:20:16Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain
